CN104284662A - 晶体及包含该晶体的药物制剂 - Google Patents

晶体及包含该晶体的药物制剂 Download PDF

Info

Publication number
CN104284662A
CN104284662A CN201380018386.2A CN201380018386A CN104284662A CN 104284662 A CN104284662 A CN 104284662A CN 201380018386 A CN201380018386 A CN 201380018386A CN 104284662 A CN104284662 A CN 104284662A
Authority
CN
China
Prior art keywords
crystal
luliconazole
crystals
present
short
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380018386.2A
Other languages
English (en)
Chinese (zh)
Inventor
增田孝明
后藤诚
宫田善之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of CN104284662A publication Critical patent/CN104284662A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380018386.2A 2012-09-14 2013-09-06 晶体及包含该晶体的药物制剂 Pending CN104284662A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012-202514 2012-09-14
JP2012202514 2012-09-14
JP2013-131504 2013-06-24
JP2013131504 2013-06-24
PCT/JP2013/074775 WO2014042231A1 (en) 2012-09-14 2013-09-06 Crystal and pharmaceutical preparation containing the same crystal

Publications (1)

Publication Number Publication Date
CN104284662A true CN104284662A (zh) 2015-01-14

Family

ID=49237577

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380018386.2A Pending CN104284662A (zh) 2012-09-14 2013-09-06 晶体及包含该晶体的药物制剂

Country Status (7)

Country Link
US (1) US9012484B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2895165B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5589130B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104284662A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN02929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2622644C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014042231A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105518002A (zh) * 2013-09-06 2016-04-20 宝丽制药股份有限公司 具有特定晶体习性的晶体和包含该晶体作为活性成分的药物组合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409789B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102933201B (zh) 2010-06-11 2015-12-16 宝丽制药股份有限公司 抗真菌药物组合物
JP5460797B1 (ja) 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
EP2895479A1 (en) 2012-09-14 2015-07-22 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
US10703744B2 (en) 2014-12-12 2020-07-07 Glenmark Life Sciences Limited Process for preparation of luliconazole
JP5951864B1 (ja) * 2015-06-05 2016-07-13 株式会社ポーラファルマ 抗ジアルジア剤
JP2017101009A (ja) 2015-12-04 2017-06-08 株式会社ポーラファルマ 抗アカントアメーバ剤及びその製造法
TR201714882A2 (tr) 2017-10-03 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194582A (zh) * 1995-07-08 1998-09-30 日本农药株式会社 抗真菌剂及其化合物和它们的制备方法
CN103012385A (zh) * 2012-02-17 2013-04-03 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
JP3278738B2 (ja) * 1995-07-08 2002-04-30 日本農薬株式会社 抗真菌剤
JP2002114680A (ja) 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd 抗真菌剤
WO2007102243A1 (ja) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. 外用の医薬組成物
ES2421613T3 (es) 2006-03-08 2013-09-04 Nihon Nohyaku Co Ltd Composición farmacéutica externa
AU2006339841B2 (en) 2006-03-08 2012-08-30 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
EP2191826B1 (en) * 2007-09-05 2017-03-08 Pola Pharma Inc. Pharmaceutical composition
JP5345937B2 (ja) 2007-09-05 2013-11-20 株式会社ポーラファルマ 抗真菌組成物
JP5453093B2 (ja) 2007-09-05 2014-03-26 株式会社ポーラファルマ 抗真菌医薬組成物
EP2395839B1 (en) 2009-02-13 2014-05-07 Topica Pharmaceuticals, Inc Anti-fungal formulation
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409789B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102933201B (zh) 2010-06-11 2015-12-16 宝丽制药股份有限公司 抗真菌药物组合物
US8728210B2 (en) 2011-07-07 2014-05-20 Hsueh Yuan Lee Exhaust gas treatment apparatus and method
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
EP2895479A1 (en) * 2012-09-14 2015-07-22 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
JP5460797B1 (ja) 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
IN2015DN02377A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-09-14 2015-09-04 Pola Pharma Inc
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194582A (zh) * 1995-07-08 1998-09-30 日本农药株式会社 抗真菌剂及其化合物和它们的制备方法
CN103012385A (zh) * 2012-02-17 2013-04-03 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105518002A (zh) * 2013-09-06 2016-04-20 宝丽制药股份有限公司 具有特定晶体习性的晶体和包含该晶体作为活性成分的药物组合物

Also Published As

Publication number Publication date
US9012484B2 (en) 2015-04-21
JP5589130B1 (ja) 2014-09-10
RU2622644C2 (ru) 2017-06-19
EP2895165A1 (en) 2015-07-22
IN2015DN02929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-18
US20140080882A1 (en) 2014-03-20
RU2015113638A (ru) 2016-11-10
WO2014042231A1 (en) 2014-03-20
EP2895165B1 (en) 2016-12-14
JP2015027972A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
CN104284662A (zh) 晶体及包含该晶体的药物制剂
CN105026390B (zh) 具有特异性结晶习性的晶型以及含有作为活性成分的该晶型的药物组合物
RU2603963C2 (ru) Кристалл, обладающий кристаллическими габитусами, и фармацевтическая композиция, полученная обработкой данного кристалла
US10358424B2 (en) Sodium salt of uric acid transporter inhibitor and crystalline form thereof
JP2015114210A (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5795694B2 (ja) 結晶及び該結晶を含有してなる医薬製剤
EP3041837B1 (en) Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient
JP5795693B2 (ja) 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
CN104447683A (zh) 一种稳定的比拉斯汀化合物
JP5623671B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
KR20180098104A (ko) 에틸 페룰레이트를 유효성분으로 포함하는 알러지 완화용 조성물
CN102600178A (zh) 一种复方盐酸布替萘芬纳米乳及其制备方法
CN115444852A (zh) 靶向线粒体的酰胺类化合物在制备抗真菌药物中的应用
HK40007140A (en) Topical composition comprising terbinafine and preparation method thereof
JP2015113341A (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP2015113343A (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150114